Virtual Reality Cognitive Therapy for Alzheimer's Disease

Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) resulting in cognitive decline affects more than 5.8 million Americans. Given the impact on quality of life, there is a great need for therapies focused on cognition. In this study, we will test the feasibility, usability, and acceptability of a novel Virtual Reality Cognitive Therapy (VRCT) for AD developed by ClarityTek, Inc. The VRCT will focus primarily on skills that impact instrumental activities of daily living (e.g., taking medications, shopping). Thirty-six individuals with mild to moderate AD/ADRD will be enrolled and will utilize the VRCT over seven weeks within their home. Enrollment will occur in cohorts of 12 individuals, so that the VRCT can be revised and optimized based on the results, prior to the next cohort. We will also hold Expert Focus Groups with clinician specialists to obtain feedback for improvement.

Inclusion criteria

• Diagnosis of mild cognitive impairment (MCI), probable Alzheimer's disease (AD) or Alzheimer's disease Related Dementias (ADRD)
• Montreal Cognitive Assessment (MoCA) score of 11-25
• Age 30-89

Exclusion criteria

• Non-English speaking
• History of seizure disorder, vertigo disorder, or severe motion sickness that would impact their ability to participate in the intervention
• History of any other serious condition that may limit their ability to participate in the intervention, as determined by the investigators.
• Inability to use the VR device (e.g., severe visual/hearing impairment, aphasia, facial injuries)